Rekombinanter IL-6R (Tocilizumab Biosimilar) Antikörper

Produktnummer ABIN5668253

Produktdetails anti-IL-6R (Tocilizumab Biosimilar) Antikörper

Target: IL-6R (Tocilizumab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Human

Klonalität: Monoklonal

Konjugat: Dieser IL-6R (Tocilizumab Biosimilar) Antikörper ist unkonjugiert

Applikation: ELISA, Inhibition Assay (InhA)

Verwendungszweck: Anti-IL-6 receptor [rhPM-1 (Tocilizumab)], Human IgG1, kappa

Spezifität: Tocilizumab binds specifically to both the membrane bound and soluble forms of human IL-6R. The IL6 receptor is a protein complex consisting of an IL-6 receptor subunit (IL6R) and interleukin 6 signal transducer Glycoprotein 130. Interleukin 6 (IL6) is a potent pleiotropic cytokine that regulates cell growth and differentiation and plays an important role in immune response.

Produktmerkmale:

Original Species of Ab: Human

Original Format of Ab: IgG1

Aufreinigung: Protein A affinity purified

Reinheit: > 98 % as determined by SDS-PAGE

Endotoxin-Niveau: Endotoxin is < 1.0 EU/mg as determined by the LAL method

Immunogen: The original antibody was generated by CDR grafting of mouse PM-1 antibody onto human REI and NEW framework regions to create rhPM-1.

Klon: RhPM-1

Isotyp: IgG1 kappa

Anwendungsinformationen

Applikationshinweise: This antibody is derived from the parental mouse clone PM-1 (PM1). Tocilizumab (TCZ) binds and neutralizes IL-6R, resulting in the inhibition of various IL-6-mediated biological activities, including inflammation-related, immunomodulatory and tissue/matrix remodelling effects. This antibody is extensively explored for its therapeutic potential in treatment of rheumatoid arthritis (PMID: 25099958, 9836380). Tocilizumab can be used in ELISA assays and is able to inhibit the growth of IL-6-dependent tumor cell lines. It inhibits sIL-6R and mIL-6R-mediated signaling. A study reported that a combination of tocilizumab and methotrexate (MTX) results in greater inhibition of joint damage and improvement in physical function than does MTX alone (PMID: 21360490). Treatment with tocilizumab results in significant improvement, maintained over time, of polyarticular-course juvenile idiopathic arthritis (pcJIA) signs and symptoms and has a safety profile consistent with that for adults with rheumatoid arthritis (PMID: 24834925). The original antibody was used for an in vivo study on ALS. Here they showed that this antibody does not affect all patients the same way. Here it was shown that the antibody lowers inflammation in patients with high inflammation and increases inflammation in patients with low inflammation (Fiala et al., 2013, PMID:23844337). tocilizumab inhibited both the transcription and secretion of cytokines and chemokines induced by apo-G37R. This showed powerful effects on the inflammation in ALS PMBC (Mizwicki et al., 2012, PMID: 23383400)

Kommentare:

NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Konservierungsmittel: ProClin

Vorsichtsmaßnahmen: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Referenzen für anti-IL-6R (Tocilizumab Biosimilar) Antikörper (ABIN5668253)

Hsieh, Hsu, Chang, Lai: "IL-6 receptor blockade corrects defects of XIAP-deficient regulatory T cells." in: Nature communications, Vol. 9, Issue 1, pp. 463, (2018) (PubMed).

Details zu IL-6R (Tocilizumab Biosimilar)

Target: IL-6R (Tocilizumab Biosimilar)

Abstract: IL-6R (Tocilizumab Biosimilar) Produkte

Substanzklasse: Biosimilar

Hintergrund: IL6R, IL-6R, CD126, MRA, atlizumab, TCZ, Interleukin-6 receptor subunit alpha, IL-6 receptor subunit alpha, IL-6R subunit alpha, IL-6R-alpha, IL-6RA, IL-6R 1, Membrane glycoprotein 80, gp80, PM1, PM-1

UniProt: P08887